Targeting Murine Mesenchymal Stem Cells to Kidney Injury Molecule-1 Improves Their Therapeutic Efficacy in Chronic Ischemic Kidney Injury

Abstract

Mesenchymal stem cells (MSC) have been experimentally used for kidney repair, but modest retention limits their efficacy. Cell‐surface coating allows modulating MSC homing and interaction with target cells. We coated mouse adipose tissue‐derived MSC with antibodies directed against kidney injury molecule‐1 (ab‐KIM1), which is upregulated in injured kidneys, and tested the hypothesis that this would enhance their therapeutic effects in ischemic kidney injury. Untreated MSC, ab‐KIM1‐coated MSC (KIM‐MSC), or vehicle, were injected systemically into the carotid artery of 2‐kidneys, 1‐clip mice 2 weeks after surgery. MSC retention in different organs was explored 24 hours, 48 hours, or 2 weeks after injection. Renal volume, perfusion, and oxygenation were studied 2 weeks after injection using magnetic resonance imaging in vivo, and renal inflammation, apoptosis, capillary density, and fibrosis ex vivo. The ab‐KIM1 coating had little effect on MSC viability or proliferation. The stenotic kidney showed upregulated KIM1 expression, selective homing, and greater retention of KIM‐MSC compared to untreated MSC and compared to other organs. KIM‐MSC‐injected mice improved renal perfusion and capillary density, and attenuated oxidative damage, apoptosis, and fibrosis compared to mice treated with vehicle or with native MSC. In conclusion, MSC coating with ab‐KIM1 increased their retention in the ischemic kidney and enhanced their therapeutic efficacy. This novel method may be useful to selectively target injured kidneys, and supports further development of strategies to enhance cell‐based treatment of ischemic kidney injury. Stem Cells Translational Medicine 2018;7:394–403

The Combination of Serum Cystatin C, Urinary Kidney Injury Molecule-1 and MELD plus Score Predicts Early Acute Kidney Injury after Liver Transplantation

“…Cystatin C is a ubiquitous protein that is freely filtered by the kidney and metabolised by the tubules. KIM-1 is a transmembrane protein that is expressed minimally in normal kidneys, but up-regulated dramatically in injured kidneys (25).…”

Human mesenchymal stromal cells and derived extracellular vesicles: Translational strategies to increase their proangiogenic potential for the treatment of cardiovascular disease

“…For example, Chou et al 70 showed that bone marrow‐derived MSCs transfected with 1,3‐fucosyltransferase VI, an enzyme transforming native CD44 on MSCs into a hematopoietic cell E‐/L‐selectin ligand, increased homing to injured endothelial cells. Similarly, Zou et al 71 coated mouse adipose tissue‐derived MSCs (AMSCs) with antibodies to kidney injury molecule‐1, a protein that is upregulated in damaged kidneys, and injected them into mice with renal artery stenosis. These AMSCs showed selective homing compared to untreated AMSCs, leading to improved renal perfusion and capillary density as well as attenuation of oxidative damage and fibrosis.…”

Stem Cell Therapy: Curcumin Does the Trick

“…Administration of MSCs forms a promising novel adjuvant treatment to improve tissue repair (Aghazadeh et al, 2018;Butler et al, 2010;Gazit, Pelled, Sheyn, Yakubovich, & Gazit, 2019;Meyer, Müller, Yang, Šulcová, & Werner, 2011). MSCs have been shown to accelerate dermal wound healing and can regenerate diverse injured organs, such as kidney, lung, and heart (Fujita, Kadota, Araya, Ochiya, & Kuwano, 2018;Maxson, Lopez, Yoo, Danilkovitch-Miagkova, & LeRoux, 2012;Ward, Abadeh, & Connelly, 2018;Zou et al, 2018).…”